• In early February 2026, Biogen reported fourth-quarter 2025 results showing quarterly sales of US$521.2 million and full-year revenue of US$9.89 billion, alongside a quarterly net loss and lower annual earnings versus 2024.
• Despite the earnings pressure, management highlighted that newer therapies such as Leqembi, Skyclarys, Xerxuve and Calcadi collectively exceeded US$1 billion in 2025 revenue, underlining Biogen’s increasing reliance on its emerging portfolio rather than legacy products.
• We’ll now examine how Biogen’s better-than-expected quarter, powered by newer products passing US$1 billion in sales, affects its investment narrative.

Outshine the giants: these 28 early-stage AI stocks could fund your retirement.

Biogen Investment Narrative Recap

To own Biogen today, you need to believe that newer neurology and rare disease launches can offset pressure in the legacy multiple sclerosis portfolio and support steady earnings. The latest quarter, which beat expectations despite a net loss, leans into that story by showing more than US$1.0 billion in revenue from newer drugs, while keeping the key short term catalyst around Leqembi’s global rollout and the main risk of overreliance on a small group of launches largely intact.

The board transition to Dr. Maria Freire as incoming Chair is particularly relevant here, given her deep background in drug development and public private partnerships. Her appointment comes as Biogen faces a dense period of clinical and regulatory events across Alzheimer’s, lupus and spinal muscular atrophy, suggesting governance is being aligned with a business that increasingly lives or dies on the success of its emerging neurology portfolio.

Yet behind this progress, investors should also be aware of growing competitive and pricing pressure in Biogen’s core MS franchise and...

Biogen's narrative projects $9.4 billion revenue and $2.1 billion earnings by 2028. This requires a 2.1% yearly revenue decline and roughly a $0.6 billion earnings increase from $1.5 billion today.

Uncover how Biogen's forecasts yield a $189.66 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were modeling Biogen to earn about US$3.3 billion by 2028 with margins above 30 percent, which is far more upbeat than consensus and could shift meaningfully as investors reassess the impact of leadership changes and concentrated bets on Alzheimer’s and rare disease launches.

Explore 7 other fair value estimates on Biogen - why the stock might be worth as much as 100% more than the current price!

Build Your Own Biogen Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 53 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.